cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Ikena Oncology Inc
6 own
2 watching
Current Price
$1.68
$0.02
(0.9%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
64.18M
52-Week High
52-Week High
6.44000
52-Week Low
52-Week Low
1.02000
Average Volume
Average Volume
0.05M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization64.18M
icon52-Week High6.44000
icon52-Week Low1.02000
iconAverage Volume0.05M
iconDividend Yield--
iconP/E Ratio--
What does the Ikena Oncology Inc do?
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Read More
How much money does Ikena Oncology Inc make?
News & Events about Ikena Oncology Inc.
Globe Newswire
1 year ago
IK-930 is a potent Hippo pathway inhibitor that selectively binds TEAD1 and broadly represses oncogenic TEAD signaling IK-930s differentiated paralog selectivity and robust repressor activity in complex with VGLL4 are key characteristics for potential tumor impact and increased therapeutic index Non...
Globe Newswire
1 year ago
BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, Ikena), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IK-175, the Companys ...
Ticker Report
1 year ago
Ikena Oncology (NASDAQ:IKNA Get Rating) had its price objective lowered by investment analysts at HC Wainwright from $26.00 to $22.00 in a research note issued to investors on Tuesday, The Fly reports. The brokerage currently has a buy rating on the stock. Separately, Credit ...
Zolmax
1 year ago
Ikena Oncology (NASDAQ:IKNA Get Rating) had its price objective lowered by investment analysts at HC Wainwright from $26.00 to $22.00 in a research note issued to investors on Tuesday, The Fly reports. The brokerage currently has a buy rating on the stock. Separately, Credit Suisse Group reduced ...
Globe Newswire
1 year ago
Novel best-in-class MEK-RAF complex inhibitor IK-595 targets RAS pathway; IND in 2023 Novel paralog-selective TEAD inhibitor IK-930 advancing as planned in dose escalation; clinical data in 2023 Company prioritizes advancement of targeted oncology portfolio; cash runway extended into 2025 BOSTON, ...
Frequently Asked Questions
Frequently Asked Questions
What is Ikena Oncology Inc share price today?
plus_minus_icon
Can Indians buy Ikena Oncology Inc shares?
plus_minus_icon
How can I buy Ikena Oncology Inc shares from India?
plus_minus_icon
Can Fractional shares of Ikena Oncology Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Ikena Oncology Inc stocks?
plus_minus_icon
What is today’s traded volume of Ikena Oncology Inc?
plus_minus_icon
What is today’s market capitalisation of Ikena Oncology Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Ikena Oncology Inc?
plus_minus_icon
What percentage is Ikena Oncology Inc down from its 52-Week High?
plus_minus_icon
What percentage is Ikena Oncology Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.68
$0.02
(0.9%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00